More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying

The Dow Jones index closed higher by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Precigen

• The Trade: Precigen, Inc. PGEN Director Randal J Kirk bought a total of 23,529,411 shares at an average price of $0.85. To acquire these shares, it cost around $20 million. The company's SVP, IP Affairs Jeffrey Thomas Perez also bought 58,823 shares.
• What's Happening: Precigen is expected to announce second quarter financial results on Aug. 14.
• What Precigen Does: Precigen Inc is a biotechnology company that develops synthetic biology solutions.

Brightcove

• The Trade: Brightcove Inc. BCOV 10% owner Jonathan Brolin acquired a total of 50,000 shares at an average price of $2.00. To acquire these shares, it cost around $99,900.
• What's Happening: On Aug. 7, Brightcove posted upbeat quarterly results.
• What Brightcove Does: Brightcove Inc is a provider of cloud-based streaming technology and services.

Xeris Biopharma

• The Trade: Xeris Biopharma Holdings, Inc. XERS Director John P. Schmid acquired a total of 4,515 shares at an average price of $2.25. The insider spent around $10,147 to buy those shares.
• What's Happening: On Aug. 8, Xeris Biopharma reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates.
• What Xeris Biopharma Does: Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology.

Read Next:

• Brinker International, Cisco And 3 Stocks To Watch Heading Into Wednesday